Qyuns Therapeutics (02509) Announces Latest Share Repurchase Update

Bulletin Express02-06 19:42

Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD 20.38 per share and a lowest price of HKD 20.06 per share, bringing the aggregate price paid to HKD 325,995.84.

Following this transaction, the company holds a total of 2,504,000 treasury shares, while the number of issued shares excluding treasury shares stands at 224,567,600. The overall total of issued shares is 227,071,600. According to the disclosure, the repurchase was made under a mandate authorized on 20 June 2025, which covers up to 22,207,160 shares. As of the announcement date, 2,504,000 shares (approximately 1.1276% of issued shares as of the mandate date) have been repurchased under this authorization. The moratorium period on new share issuances or transfers of treasury shares after the purchase extends to 08 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133624375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133624375","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics (02509) Announces Latest Share Repurchase Update","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD 20.38 per share and a lowest price of HKD 20.06 per share, bringing the aggregate price paid to HKD 325,995.84.</p>\n<p>Following this transaction, the company holds a total of 2,504,000 treasury shares, while the number of issued shares excluding treasury shares stands at 224,567,600. The overall total of issued shares is 227,071,600. According to the disclosure, the repurchase was made under a mandate authorized on 20 June 2025, which covers up to 22,207,160 shares. As of the announcement date, 2,504,000 shares (approximately 1.1276% of issued shares as of the mandate date) have been repurchased under this authorization. The moratorium period on new share issuances or transfers of treasury shares after the purchase extends to 08 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics (02509) Announces Latest Share Repurchase Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics (02509) Announces Latest Share Repurchase Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-06 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD 20.38 per share and a lowest price of HKD 20.06 per share, bringing the aggregate price paid to HKD 325,995.84.</p>\n<p>Following this transaction, the company holds a total of 2,504,000 treasury shares, while the number of issued shares excluding treasury shares stands at 224,567,600. The overall total of issued shares is 227,071,600. According to the disclosure, the repurchase was made under a mandate authorized on 20 June 2025, which covers up to 22,207,160 shares. As of the announcement date, 2,504,000 shares (approximately 1.1276% of issued shares as of the mandate date) have been repurchased under this authorization. The moratorium period on new share issuances or transfers of treasury shares after the purchase extends to 08 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1133624375","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133624375","pubTimestamp":1770378150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics(02509)公布最新股份回购更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (02509) disclosed a share repurchase conducted on 06 February 2026. The company repurchased 16,200 H shares on the Hong Kong Stock Exchange at a highest price of HKD 20.38 per share and a lowest price of HKD 20.06 per share, bringing the aggregate price paid to HKD 325,995.84.\nFollowing this transaction, the company holds a total of 2,504,000 treasury shares, while the number of issued shares excluding treasury shares stands at 224,567,600. The overall total of issued shares is 227,071,600. According to the disclosure, the repurchase was made under a mandate authorized on 20 June 2025, which covers up to 22,207,160 shares. As of the announcement date, 2,504,000 shares (approximately 1.1276% of issued shares as of the mandate date) have been repurchased under this authorization. The moratorium period on new share issuances or transfers of treasury shares after the purchase extends to 08 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133624375","isCrawlerRequest":true}